Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) kicked off on Tuesday, up 0.92% from the previous trading day, before settling in for the closing price of $996.05. Over the past 52 weeks, REGN has traded in a range of $769.19-$1211.20.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 19.99%. While this was happening, its average annual earnings per share was recorded 2.77%. With a float of $106.30 million, this company’s outstanding shares have now reached $107.60 million.
The extent of productivity of a business whose workforce counts for 13450 workers is very important to gauge. In terms of profitability, gross margin is 86.08%, operating margin of 29.18%, and the pretax margin is 34.01%.
Regeneron Pharmaceuticals, Inc. (REGN) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Regeneron Pharmaceuticals, Inc. is 3.55%, while institutional ownership is 86.56%. The most recent insider transaction that took place on Oct 01 ’24, was worth 104,878. In this transaction Director of this company sold 100 shares at a rate of $1048.78, taking the stock ownership to the 17,582 shares. Before that another transaction happened on Oct 01 ’24, when Company’s EVP Commercial sold 1,000 for $1054.06, making the entire transaction worth $1,054,060. This insider now owns 12,931 shares in total.
Regeneron Pharmaceuticals, Inc. (REGN) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 2.77% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.00% during the next five years compared to 10.31% growth over the previous five years of trading.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Trading Performance Indicators
Take a look at Regeneron Pharmaceuticals, Inc.’s (REGN) current performance indicators. Last quarter, stock had a quick ratio of 4.62. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.21. Likewise, its price to free cash flow for the trailing twelve months is 33.29.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 37.76, a number that is poised to hit 11.83 in the next quarter and is forecasted to reach 48.54 in one year’s time.
Technical Analysis of Regeneron Pharmaceuticals, Inc. (REGN)
The latest stats from [Regeneron Pharmaceuticals, Inc., REGN] show that its last 5-days average volume of 0.78 million was superior to 0.49 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 9.33%. Additionally, its Average True Range was 26.14.
During the past 100 days, Regeneron Pharmaceuticals, Inc.’s (REGN) raw stochastic average was set at 20.46%, which indicates a significant increase from 7.20% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 27.92% in the past 14 days, which was higher than the 20.78% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1,120.43, while its 200-day Moving Average is $1,007.94. Now, the first resistance to watch is $1,011.16. This is followed by the second major resistance level at $1,017.07. The third major resistance level sits at $1,026.15. If the price goes on to break the first support level at $996.18, it is likely to go to the next support level at $987.10. The third support level lies at $981.20 if the price breaches the second support level.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Key Stats
The company with the Market Capitalisation of 110.80 billion has total of 110,186K Shares Outstanding. Its annual sales at the moment are 13,117 M in contrast with the sum of 3,954 M annual income. Company’s last quarter sales were recorded 3,547 M and last quarter income was 1,432 M.
